Ritu Salani
Ritu Salani
Adresă de e-mail confirmată pe mednet.ucla.edu
Citat de
Citat de
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer
SE Bojesen, KA Pooley, SE Johnatty, J Beesley, K Michailidou, JP Tyrer, ...
Nature genetics 45 (4), 371-384, 2013
Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology clinical practice guideline
AA Wright, K Bohlke, DK Armstrong, MA Bookman, WA Cliby, ...
Gynecologic oncology 143 (1), 3-15, 2016
Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations
R Salani, FJ Backes, MFK Fung, CH Holschneider, LP Parker, RE Bristow, ...
American journal of obstetrics and gynecology 204 (6), 466-478, 2011
Identification of six new susceptibility loci for invasive epithelial ovarian cancer
KB Kuchenbaecker, SJ Ramus, J Tyrer, A Lee, HC Shen, J Beesley, ...
Nature genetics 47 (2), 164-171, 2015
Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study
D Tewari, JJ Java, R Salani, DK Armstrong, M Markman, T Herzog, ...
Obstetrical & Gynecological Survey 70 (8), 505-506, 2015
Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel/carboplatin in high-intermediate and high-risk early-stage endometrial cancer
ME Randall, V Filiaci, DS McMeekin, V Von Gruenigen, H Huang, ...
Journal of Clinical Oncology 37 (21), 1810, 2019
An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations
R Salani, N Khanna, M Frimer, RE Bristow, L Chen
Gynecologic oncology 146 (1), 3-10, 2017
Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome
R Salani, A Santillan, ML Zahurak, RL Giuntoli, GJ Gardner, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2007
Cancer and pregnancy: an overview for obstetricians and gynecologists
R Salani, CC Billingsley, SM Crafton
American journal of obstetrics and gynecology 211 (1), 7-14, 2014
Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug …
R Salani, RJ Kurman, R Giuntoli, G Gardner, R Bristow, TL Wang, IM Shih
International Journal of Gynecologic Cancer 18 (3), 2008
Amplicon profiles in ovarian serous carcinomas
K Nakayama, N Nakayama, N Jinawath, R Salani, RJ Kurman, IM Shih, ...
International journal of cancer 120 (12), 2613-2617, 2007
A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival
K Nakayama, N Nakayama, B Davidson, JJC Sheu, N Jinawath, ...
Proceedings of the National Academy of Sciences 103 (49), 18739-18744, 2006
Adenocarcinoma in situ of the uterine cervix: a metaanalysis of 1278 patients evaluating the predictive value of conization margin status
R Salani, I Puri, RE Bristow
American journal of obstetrics and gynecology 200 (2), 182. e1-182. e5, 2009
BRCA mutation in ovarian cancer: testing, implications and treatment considerations
RT Neff, L Senter, R Salani
Therapeutic advances in medical oncology 9 (8), 519-531, 2017
Breast and gynecologic cancer-related extremity lymphedema: a review of diagnostic modalities and management options
P Tiwari, M Coriddi, R Salani, SP Povoski
World journal of surgical oncology 11, 1-13, 2013
Do survivorship care plans impact patients' evaluations of care? A randomized evaluation with gynecologic oncology patients
BM Brothers, A Easley, R Salani, BL Andersen
Gynecologic oncology 129 (3), 554-558, 2013
Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer
R Salani, A Axtell, M Gerardi, C Holschneider, RE Bristow
Gynecologic oncology 108 (2), 271-275, 2008
Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival
CM Cosgrove, DE Cohn, H Hampel, WL Frankel, D Jones, JP McElroy, ...
Gynecologic oncology 146 (3), 588-595, 2017
Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants
DR Barnes, MA Rookus, L McGuffog, G Leslie, TM Mooij, J Dennis, ...
Genetics in Medicine 22 (10), 1653-1666, 2020
NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021: Featured Updates to the NCCN Guidelines
NR Abu-Rustum, CM Yashar, K Bradley, SM Campos, J Chino, HS Chon, ...
Journal of the National Comprehensive Cancer Network 19 (8), 888-895, 2021
Sistemul nu poate realiza operația în acest moment. Încercați din nou mai târziu.
Articole 1–20